Literature DB >> 12806280

Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12.

Bohuslav Melichar1, Renato Lenzi, Michael Rosenblum, Andrzej P Kudelka, John J Kavanagh, Karolina Melicharova, Stacie Templin, Michael E Garcia, James L Abbruzzese, Ralph S Freedman.   

Abstract

Activated monocytes-macrophages may be associated with antitumor activity, and activation of these cells by certain cytokines, primarily interferon gamma (IFN-gamma), can be indicated by alterations in the concentrations of neopterin, nitrate, or tryptophan. Specimens of peritoneal fluid were obtained from patients with intra-abdominal neoplasia who were undergoing treatment in a phase I trial of weekly intraperitoneal recombinant interleukin-12 (rhIL-12), an inducer of IFN-gamma. Concentrations of neopterin, nitrate, tryptophan, IFN-gamma, and tumor necrosis factor alpha (TNF-alpha) were determined at various times during the first 48 hours in 11 patients who received intraperitoneal rhIL-12 in doses ranging from 100 to 1,500 ng/kg. An increase in peritoneal fluid nitrate concentrations was observed in nine of these patients. Increased concentrations of TNF-alpha and IFN-gamma were detected in 3 of 9 and 8 of 11 patients, respectively. Increased peritoneal fluid neopterin concentrations were detected by 24 hours after the injection in all patients studied. A significant increase in the ascitic fluid neopterin level could still be detected after 1 or 2 weeks of treatment (mean +/- standard error, 7.8 +/- 1.5 nM vs. 4.6 +/- 0.3 nM; Wilcoxon test, p = 0.0019), which is consistent with monocyte-macrophage activation. In contrast, the tryptophan concentration was lower (4.7 +/- 1.1 microM vs. 6.1 +/- 1.2 microM; p = 0.0428) after 1 or 2 weeks of treatment. There was a significant correlation between the dose of rhIL-12 and posttreatment neopterin concentrations (r(s) = 0.559, p = 0.0102). The intraperitoneal delivery of rhIL-12 appears to be associated with an immediate, sustained, and dose-dependent increase in peritoneal fluid neopterin, associated in most patients by an increase in IFN-gamma and in certain patients by an increase in nitrate and a decrease in tryptophan concentrations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12806280     DOI: 10.1097/00002371-200305000-00010

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  5 in total

Review 1.  Neopterin as a biomarker of immune response in cancer patients.

Authors:  Bohuslav Melichar; Martina Spisarová; Marie Bartoušková; Lenka Kujovská Krčmová; Lenka Javorská; Hana Študentová
Journal:  Ann Transl Med       Date:  2017-07

2.  HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates.

Authors:  Lena A Basile; Dolph Ellefson; Zoya Gluzman-Poltorak; Katiana Junes-Gill; Vernon Mar; Sarita Mendonca; Joseph D Miller; Jamie Tom; Alice Trinh; Timothy K Gallaher
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

Review 3.  IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines.

Authors:  Zhiliang Jia; Dristhi Ragoonanan; Kris Michael Mahadeo; Jonathan Gill; Richard Gorlick; Elizabeth Shpal; Shulin Li
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

4.  Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma.

Authors:  Renato Lenzi; Robert Edwards; Carl June; Michael V Seiden; Michael E Garcia; Michael Rosenblum; Ralph S Freedman
Journal:  J Transl Med       Date:  2007-12-12       Impact factor: 5.531

5.  Neopterin, kynurenine and tryptophan as new biomarkers for early detection of rectal anastomotic leakage.

Authors:  Tomas Dusek; Julius Orhalmi; Otakar Sotona; Lenka Kujovska Krcmova; Lenka Javorska; Josef Dolejs; Jiri Paral
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-02-07       Impact factor: 1.195

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.